Work

Supplementary Figure S7 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 7. Exploratory analysis of median overall survival (A-C) and progression-free survival (B-D) according to TMB status in NI (A-B) and N-CT (C-D) treatment arm. TMB low (yellow line; n = 30/40) vs TMB high (blue line; n = 43/23). OS: Overall survival; PFS: progression-free survival.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4408535697
Cites:
Cited by:
Related to: 10